



# Identification of alsterpaullone as a novel small molecule inhibitor to target group 3 medulloblastoma

## Supplementary Material


**a**



**b**




**Supplementary Figure 1. a** Representative H&E staining demonstrates that mice bearing D458 tumors treated with piperlongumine, alsterpaullone and rottlerin have smaller medulloblastomas in the cerebellum. Scale bar: 500  $\mu$ m. **b** Kaplan-Meier survival curves of D458 medulloblastoma xenografts treated with flunarizine (50 mg/Kg, daily for 2 weeks; n = 6) or vehicle control (10% DMSO; n = 12). Survival differences were calculated using a log-rank test.




**Supplementary Figure 2.** Biological pathways and processes up- and down-regulated by alsterpaullone. Gene Set Enrichment Analysis (GSEA) comparing gene sets up- and down-regulated by alsterpaullone (ALP) in D458 and D425 medulloblastoma cells ( $FDR < 0.05$ ;  $p < 0.01$ ). Cytoscape and Enrichment Map were used for visualization of the GSEA results. The enriched gene sets were grouped by their similarity, represented as nodes, and mapped as a network. The size of each node determines the total number of genes within each gene set.

**a**



**b**



**Supplementary Figure 3.** Alsterpaullone reverses Group 3 medulloblastoma gene expression signature as shown by (a) the C-MAP analysis and (b) the Significance Analysis of Microarrays (SAM) plot.


a

cmap name	mean	n	enrichment	p-value	specificity	% non-null
piperlongumine	-0.061	2	-0.474	0.59627	0.7342	50

#### piperlongumine

rank	batch	cmap name	dose	cell	score	up	down	instance_id
614	641	piperlongumine	13 $\mu$ M	HL60	.499	.067	-.095	1764
5943	662	piperlongumine	13 $\mu$ M	MCF7	-.621	-.128	.130	2757

b



**Supplementary Figure 4.** The gene expression profile of Group 3 medulloblastomas is not affected by piperlongumine as determined by (a) the C-MAP analysis and (b) the Significance Analysis of Microarrays (SAM) plot.